Track topics on Twitter Track topics that are important to you
Boehringer Ingelheim has formed an alliance with OSE Immunotherapeutics to develop a SIRP-alpha antagonist compound to treat advanced solid tumours....Read More... The post Boehringer and OSE Immunoth...
French groups OSE Immunotherapeutics and Servier have inked a pact to develop and commercialize the newly formed biotech's interleukin-7 antagonist...
Boehringer Ingelheim has entered into an exclusive worldwide collaboration and license agreement with OSE Immunotherapeutics for the development of a new checkpoint inhibitor to treat solid tumors.
Veteran healthcare investor will support OSE's growth strategy and ongoing business development activities Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), tod...
In a deal valued at over €1.1bn ($1.39bn) OSE Immunotherapeutics SA exclusively licensed Boehringer Ingelheim GMBH worldwide rights to monoclonal antibody OSE172 (Effi-dem).
Amsterdam, March 12-14, 2018 Regulatory News: OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE), announces it will be featured as a presenting company at the 12th Annual Conferen...
Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
Regulatory News: OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE), today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Science...
The investigators propose to evaluate cabozantinib in combination with durvalumab in previously treated patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malig...
M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...
Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of i...
Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focus...
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a...
We have published hundreds of Artielle ImmunoTherapeutics news stories on BioPortfolio along with dozens of Artielle ImmunoTherapeutics Clinical Trials and PubMed Articles about Artielle ImmunoTherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Artielle ImmunoTherapeutics Companies in our database. You can also find out about relevant Artielle ImmunoTherapeutics Drugs and Medications on this site too.